APA (7th ed.) Citation

G, F., C, S., R, L., A, P., PV, N., E, Z., . . . E, F. (2024). Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS-Meet-URO 26 Study. Clinical genitourinary cancer, 22(5), 102185. https://doi.org/10.1016/j.clgc.2024.102185

Chicago Style (17th ed.) Citation

G, Fotia, et al. "Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS-Meet-URO 26 Study." Clinical Genitourinary Cancer 22, no. 5 (2024): 102185. https://doi.org/10.1016/j.clgc.2024.102185.

MLA (9th ed.) Citation

G, Fotia, et al. "Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS-Meet-URO 26 Study." Clinical Genitourinary Cancer, vol. 22, no. 5, 2024, p. 102185, https://doi.org/10.1016/j.clgc.2024.102185.